

# Resource Summary Report

Generated by [RRID](#) on Aug 11, 2026

## ESTIMATE

RRID:SCR\_026090

Type: Tool

### Proper Citation

ESTIMATE (RRID:SCR\_026090)

### Resource Information

**URL:** <https://github.com/oicr-gsi/ESTIMATE>

**Proper Citation:** ESTIMATE (RRID:SCR\_026090)

**Description:** Software application provides researchers with scores for tumor purity, level of stromal cells present, and infiltration level of immune cells in tumor tissues based on expression data.

**Resource Type:** software application, source code, software resource

**Keywords:** scores, tumor purity, stromal cells, infiltration level, immune cells, tumor tissues, expression data,

**Availability:** Free, Available for download, Freely available,

**Resource Name:** ESTIMATE

**Resource ID:** SCR\_026090

**License:** MIT license

**Record Creation Time:** 20241123T053252+0000

**Record Last Update:** 20260810T040923+0000

### Ratings and Alerts

No rating or validation information has been found for ESTIMATE.

No alerts have been found for ESTIMATE.

### Data and Source Information

## Usage and Citation Metrics

We found 22 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [RRID](#) .

Huang KK, et al. (2026) Mutational Signatures and Clonal Hematopoiesis in Intestinal Metaplasia across Countries with Varying Stomach Cancer Incidence. *Cancer discovery*, 16(3), 497.

Gui S, et al. (2026) Multiomics Profiling Reveals Distinct Immunosuppression and Metabolic Dysregulation in Aggressive Subtypes of Thyroid Cancer. *Molecular & cellular proteomics : MCP*, 25(3), 101513.

Zhu Y, et al. (2026) Multi-omics exploration of hypoxia in gastric cancer. *World journal of surgical oncology*, 24(1).

Wang XX, et al. (2026) Modulating the tumor immune phenotypes by radiotherapy: formulating and validating the combination therapy of radiation, PD-L1, and TIM-3 blockade in colorectal cancer. *Journal for immunotherapy of cancer*, 14(2).

Ma Z, et al. (2026) Elevated PTK6 expression is associated with tumor immune microenvironment remodeling and predicts poor prognosis in endometrial carcinoma. *Frontiers in medicine*, 13, 1842564.

Zhang W, et al. (2026) Unveiling the comorbidity hub: WT1 drives renal cancer progression in chronic kidney disease and confers sirolimus vulnerability. *Experimental and therapeutic medicine*, 32(2), 220.

Cao Z, et al. (2026) Study on the mechanism of PSENEN in modulating cisplatin resistance in NSCLC through stromal cell interactions. *International immunopharmacology*, 169, 116037.

Zhao W, et al. (2026) A Prognostic Signature for Lung Adenocarcinoma in Patients Who Have Never Smoked. *Cancer discovery*, 16(3), 460.

Li S, et al. (2026) PRECISE: A Prognostic Thyrocyte-Derived Gene Signature for Papillary Thyroid Carcinoma. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(13), 2667.

Li B, et al. (2025) A practical distribution pattern of  $\alpha$ -SMA-positive carcinoma associated fibroblasts indicates poor prognosis of patients with pancreatic ductal adenocarcinoma. *Translational oncology*, 52, 102282.

Liu Y, et al. (2025) Identification and Validation of Four Serum Biomarkers With Optimal Diagnostic and Prognostic Potential for Gastric Cancer Based on Machine Learning Algorithms. *Cancer medicine*, 14(6), e70659.

Gao M, et al. (2025) Targeting the KLF5/PI3K/AKT axis as a therapeutic strategy to overcome neoadjuvant chemoresistance in colorectal cancer. *Frontiers in immunology*, 16, 1593639.

Da Y, et al. (2025) Transient Receptor Potential Melastatin 4 (TRPM4) is associated with an immuno-stimulatory TME and better prognosis in BLCA. *Discover oncology*, 16(1), 2257.

Zhao W, et al. (2025) A prognostic signature for lung adenocarcinoma in people who have never smoked. *bioRxiv : the preprint server for biology*.

Suzuki H, et al. (2025) GALNT7 Stratifies dMMR/MSI Colorectal Cancer into Distinct Molecular Subsets Associated with Prognosis and PD-L1 Expression. *Cancer research communications*, 5(9), 1530.

Liu Z, et al. (2025) Transcriptomic and microenvironment characteristics of triple-negative breast cancer under three different neoadjuvant treatment regimens. *Breast cancer research and treatment*.

Sveen A, et al. (2024) Evolutionary mode and timing of dissemination of high-grade serous carcinomas. *JCI insight*, 9(3).

Fan Z, et al. (2024) A transcriptome based molecular classification scheme for cholangiocarcinoma and subtype-derived prognostic biomarker. *Nature communications*, 15(1), 484.

Wu J, et al. (2024) Identification of disulfidptosis-related clusters and construction of a disulfidptosis-related gene prognostic signature in triple-negative breast cancer. *Heliyon*, 10(12), e33092.

Yu Y, et al. (2023) Construction of a CCL20-centered circadian-signature based prognostic model in cervical cancer. *Cancer cell international*, 23(1), 92.